Coagulopathy in COVID-19: Manifestations and management.
Level V
Where this comes from
- Record sourced from PubMed, PMID 32409435.
- Also identified by DOI 10.3949/ccjm.87a.ccc024.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Severe COVID-19 illness is associated with intense inflammation, leading to high rates of thrombotic complications that increase morbidity and mortality. Markedly elevated levels of D-dimer with normal fibrinogen levels are the hallmark laboratory findings of severe COVID-19- associated coagulopathy. Prophylaxis against venous thromboembolism is paramount for all hospitalized patients, with more aggressive prophylaxis and screening recommended for patients with D-dimer levels above 3.0 μg/mL. Point-of-care ultrasonography is the imaging method of choice for patients at high risk, as it entails minimal risk of exposing providers to the virus.
Medical subject headings
- Anticoagulants
- Betacoronavirus
- Blood Coagulation Disorders
- Coronavirus Infections
- Fibrin Fibrinogen Degradation Products
- Monitoring, Physiologic
- Pandemics
- Pneumonia, Viral